‣ General

• Male or female patients aged ≥ 18 years of age, at the time of informed consent, with histological or cytological confirmation of AML

• Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archival tumor tissue

• Ability to swallow and retain oral medication

• Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2 at screening

• In the opinion of the investigator, all other relevant medical conditions must be well-managed and stable for at least 28 days prior to first administration of study drug

• Patients with pathologically confirmed/documented AML or MDS, as defined by the 2022 European LeukaemiaNet (ELN) recommendations, or CMML, as defined by World Health Organization (WHO) criteria, who have relapsed from or are refractory to previous therapy and have failed all (or are not eligible for/intolerant to) available approved therapies for their disease.

• Patients with relapsed/refractory FLT3 WT AML.

• Previous exposure to venetoclax, hypomethylating agent and/or FLT3 inhibitors (gilteritinib, midostorin, quizartinib, sorafenib) is allowed for relapsed/refractory AML patients.

⁃ Mutation status of patients must be known at trial entry.

⁃ Female patients should either be of non-child-bearing potential or must agree to use highly effective methods of contraception from Screening until 6 months following administration of the last dose of study drug

⁃ Male patients must use double barrier contraception from enrolment through treatment and for 6 months following administration of the last dose of study drug